论文部分内容阅读
目的厄洛替尼(商品名:特罗凯)是治疗非小细胞肺癌的一种新型靶向药物,近些年来临床应用甚广,但副作用较多,其中以皮疹最为多见,且最令患者难以接受。本研究旨在观察应用特罗凯前后小鼠在表皮、病理、免疫组化等方面的改变,复制特罗凯所致皮疹的动物模型,为临床外用药物治疗皮疹提供模型。方法使用BALB/c雌性小鼠20只,随机分成4组。实验组(Ⅱ、Ⅲ、Ⅳ组)用浓度为10 g/L的特罗凯溶液按100 mg/kg灌胃,对照组(Ⅰ组)以等体积去离子水灌胃,每天1次。于给药前24 h在小鼠头颈、背、腰处脱毛,实验结束后剪取颈部、背部、腰部皮肤并观察实验组、对照组小鼠在肉眼皮肤、病理切片、免疫组化等方面的改变。结果 (1)四组小鼠之间在毛发再生天数、毛发完全再生天数、脱屑时间、出现皮疹时间、毛孔扩张数等5方面的差异存在统计学意义(P<0.01或P<0.05);(2)Ki67:四组间差异无统计学意义(P>0.05)。结论 (1)此次实验印证了许多研究者关于“EGFRIs导致的皮疹为一种炎症反应”的观点;(2)该皮疹模型可靠实用,具有可重复性,适用于“EGFRIs所致皮疹动物模型”的大批建立,可推广以供临床、试验、研究所用。
Objective Erlotinib (trade name: Tarceva) is a new type of targeted drug for the treatment of non-small cell lung cancer. It has been widely used in clinical practice in recent years, but has many side effects, of which the rash is the most common and the most Patient unacceptable. The purpose of this study was to observe the changes in epidermis, pathology and immunohistochemistry of Tarceva mice before and after the application of Tarceva to replicate the animal model of Tarceva rash and provide a model for the clinical treatment of skin rashes. Methods Twenty BALB / c female mice were randomly divided into 4 groups. The experimental group (Ⅱ, Ⅲ, Ⅳ) was fed with 100 mg / kg Tarceva with the concentration of 10 g / L, and the control group (Ⅰ) with the same volume of deionized water once a day. At 24 h before the administration, the hair was removed from the head, neck, back and waist of the mice. After the experiment, the skin of the neck, back and waist were cut out and the skin of the experimental group and the control group were observed, such as naked skin, pathological section and immunohistochemistry Change. Results (1) There was statistical significance (P <0.01 or P <0.05) between the four groups of mice in terms of days of hair regeneration, number of days of complete regeneration of hair, desquamation time, rash time and number of enlarged pores. (2) Ki67: There was no significant difference among the four groups (P> 0.05). Conclusions (1) This experiment confirms the opinion of many investigators that “the rashes caused by EGFRIs are an inflammatory response”; (2) this rash model is reliable, practical and reproducible and is suitable for “EGFRIs-induced Rash animal model ”a large number of establishment, can be extended for clinical, experimental, research use.